Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo

Phase 2

Completed

Brief Summary: This study aims to demonstrate that the new medicine AUT00063 is effective and safe in the treatment of tinnitus.

Detailed Description: Reduced activity at certain sites in the brain (called "voltage-gated potassium channels") has been linked to hearing problems, like age-related loss of hearing or tinnitus (a 'ringing' or buzzing noise in the ears).

AUT00063 is an experimental new medicine that has been developed to improve the action of these specific channels and so treat the brain component of these hearing problems.

The main purpose of this study is to try to demonstrate an improvement in the severity of tinnitus after 4 weeks of treatment with the study medicine or the placebo (dummy drug which does not contain the medication). Subjects will undergo a safety follow-up after the treatment period.

Safety and efficacy will be determined by looking at a number of assessments (physical examinations, blood sampling, hearing assessments, questionnaires, etc.) and in case of any serious medical event during the study. The amount of drug in the blood will also be measured.

It is expected that up to 152 people with tinnitus may take part in the study. The study participants will be recruited at around 16 Hospital sites in the UK.

Recruitment & Eligibility

Inclusion Criteria

English-speaking, who are UK residents registered with a UK General Practitioner;
Experiencing stable tinnitus (consistent from day to day)
Tinnitus has existed for not less than 6 months, and not more than 18 months - Contraceptive methods must be used before and for at least 30 days after the stop of the study treatment.

Exclusion Criteria

Severe hearing impairment such that verbal communication is unreliable;
History of important cardiac, endocrine, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases deemed clinically significant at the time of the study by the Investigator and which might be jeopardised by entering the study;
Moderate or severe depression or generalised anxiety
Participation in any clinical research study evaluating another investigational drug or therapy within 30 days of starting the investigational treatment
Participation in hearing study, involving an intervention, within 3 months from last study visit;
Central nervous system pathologies e.g. Multiple Sclerosis, Parkinson's disease;
Tinnitus as a concomitant symptom of a known otological condition (including but not limited to otitis externa, otitis media, otosclerosis, cholesteatoma, Ménière's disease or other vestibular problems, acoustic neuroma, or temporo-mandibular joint disorder);
Pulsatile tinnitus (rhythmical sounds that often beat in time with the heartbeat);
Intermittent tinnitus (comes and goes from one day to the next);
Surgery or medical condition that might would be expected to significantly affect absorption of medicines;

Arm && Interventions

Group	Intervention	Description
AUT00063	AUT00063	4 capsules of 200 mg of the new medicine, AUT00063, to take orally with food for 4 weeks.
Placebo	Placebo	4 capsules of placebo, to take orally with food for 4 weeks.

Primary Outcome Measures

Name	Time	Method
Change in subjective Tinnitus after 4 weeks treatment	28 days	To compare the change from baseline (D1 to D28) of the Tinnitus Functional Index overall score between AUT00063 (800 mg) and placebo.

Secondary Outcome Measures

Name	Time	Method
Change in Tinnitus Loudness matching after 4 weeks of treatment	28 days	Changes from baseline (D1) at Day 28 between treatment groups in Tinnitus loudness matching (LM).
To further investigate the safety and tolerability profile of repeat administration of AUT00063 (assessing vital signs, physical examination, laboratory exams and ECG)	42 days	To investigate the safety and tolerability of AUT00063 by assessing vital signs, physical examination, laboratory exams and ECG
Pharmacokinetic of AUT00063 (Exposure of AUT00063 ng/ml, measured as AUT00063 plasma levels)	at day 28	Exposure of AUT00063 ng/ml, measured as AUT00063 plasma levels at Day 28

Locations (18): Bristol Royal Infirmary
🇬🇧
Bristol, United Kingdom
Cambridge University Hospitals NHS Trust
🇬🇧
Cambridge, United Kingdom
Freeman Hospital
🇬🇧
Newcastle, United Kingdom
Nottingham University Hospitals NHS Trust
🇬🇧
Nottingham, United Kingdom
University College London Hospital NHS Foundation Trust
🇬🇧
London, United Kingdom
Frimley Health NHS Foundation Trust
🇬🇧
Frimley, United Kingdom
Norfolk and Norwich University Hospital Foundation Trust
🇬🇧
Norwich, United Kingdom
Birmingham University Hospital
🇬🇧
Birmingham, United Kingdom
Portsmouth Hospitals NHS Trust
🇬🇧
Portsmouth, United Kingdom
Shrewsbury and Telford Hospital NHS Trust
🇬🇧
Telford, United Kingdom
University Hospital of North Staffordshire
🇬🇧
Stoke-on-Trent, United Kingdom
Bradford Teaching Hospital
🇬🇧
Bradford, United Kingdom
Lister Hospital
🇬🇧
Stevenage, United Kingdom
Salford Royal Hospital
🇬🇧
Salford, United Kingdom
The Pennine Acute Hospitals NHS Trust
🇬🇧
Manchester, United Kingdom
Royal Hallamshire Hospital, Sheffield
🇬🇧
Sheffield, United Kingdom
Wrightington Hospital
🇬🇧
Wigan, United Kingdom
Derriford Plymouth NHS Trust
🇬🇧
Plymouth, United Kingdom